- Home
- UROY vs ADCT Comparison
UROY vs ADCT Comparison
Compare UROY & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- ADCT
- Stock Information
- Founded
- UROY 2017
- ADCT 2011
- Country
- UROY Canada
- ADCT Switzerland
- Employees
- UROY N/A
- ADCT N/A
- Industry
- UROY
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- UROY
- ADCT Health Care
- Exchange
- UROY Nasdaq
- ADCT Nasdaq
- Market Cap
- UROY 438.3M
- ADCT 398.2M
- IPO Year
- UROY N/A
- ADCT 2020
- Fundamental
- Price
- UROY $3.18
- ADCT $3.34
- Analyst Decision
- UROY Strong Buy
- ADCT Strong Buy
- Analyst Count
- UROY 2
- ADCT 6
- Target Price
- UROY $4.00
- ADCT $7.80
- AVG Volume (30 Days)
- UROY 2.7M
- ADCT 644.5K
- Earning Date
- UROY 09-11-2025
- ADCT 11-06-2025
- Dividend Yield
- UROY N/A
- ADCT N/A
- EPS Growth
- UROY N/A
- ADCT N/A
- EPS
- UROY N/A
- ADCT N/A
- Revenue
- UROY $35,266,447.00
- ADCT $77,246,000.00
- Revenue This Year
- UROY $228.36
- ADCT $12.71
- Revenue Next Year
- UROY N/A
- ADCT $6.59
- P/E Ratio
- UROY N/A
- ADCT N/A
- Revenue Growth
- UROY 14.29
- ADCT 15.73
- 52 Week Low
- UROY $1.43
- ADCT $1.05
- 52 Week High
- UROY $3.34
- ADCT $3.97
- Technical
- Relative Strength Index (RSI)
- UROY 58.40
- ADCT 56.14
- Support Level
- UROY $3.09
- ADCT $3.20
- Resistance Level
- UROY $3.32
- ADCT $3.38
- Average True Range (ATR)
- UROY 0.15
- ADCT 0.16
- MACD
- UROY -0.01
- ADCT -0.00
- Stochastic Oscillator
- UROY 58.23
- ADCT 56.15
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).